Fares Iman, Chagraoui Jalila, Gareau Yves, Gingras Stéphane, Ruel Réjean, Mayotte Nadine, Csaszar Elizabeth, Knapp David J H F, Miller Paul, Ngom Mor, Imren Suzan, Roy Denis-Claude, Watts Kori L, Kiem Hans-Peter, Herrington Robert, Iscove Norman N, Humphries R Keith, Eaves Connie J, Cohen Sandra, Marinier Anne, Zandstra Peter W, Sauvageau Guy
Molecular Genetics of Stem Cells Laboratory, Institute of Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC, Canada.
Medicinal Chemistry, IRIC, University of Montreal, Montreal, QC, Canada.
Science. 2014 Sep 19;345(6203):1509-12. doi: 10.1126/science.1256337.
The small number of hematopoietic stem and progenitor cells in cord blood units limits their widespread use in human transplant protocols. We identified a family of chemically related small molecules that stimulates the expansion ex vivo of human cord blood cells capable of reconstituting human hematopoiesis for at least 6 months in immunocompromised mice. The potent activity of these newly identified compounds, UM171 being the prototype, is independent of suppression of the aryl hydrocarbon receptor, which targets cells with more-limited regenerative potential. The properties of UM171 make it a potential candidate for hematopoietic stem cell transplantation and gene therapy.
脐带血单位中造血干细胞和祖细胞数量较少,限制了它们在人类移植方案中的广泛应用。我们鉴定出了一类化学结构相关的小分子,它们能在体外刺激人类脐带血细胞的扩增,这些细胞能够在免疫缺陷小鼠体内重建人类造血功能至少6个月。这些新鉴定出的化合物(以UM171为原型)的强大活性独立于芳烃受体的抑制作用,芳烃受体靶向具有更有限再生潜力的细胞。UM171的特性使其成为造血干细胞移植和基因治疗的潜在候选物。